KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $157.2 million.

  • Acadia Pharmaceuticals' Free Cash Flow rose 16.97% to $73.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.1 million, marking a year-over-year decrease of 2.25%. This contributed to the annual value of $157.2 million for FY2024, which is 844.01% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Free Cash Flow of $157.2 million as of FY2024, which was up 844.01% from $16.7 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Free Cash Flow high stood at $157.2 million for FY2024, and its period low was -$143.8 million during FY2020.
  • For the 3-year period, Acadia Pharmaceuticals' Free Cash Flow averaged around $19.9 million, with its median value being $16.7 million (2023).
  • Data for Acadia Pharmaceuticals' Free Cash Flow shows a peak YoY spiked of 844.01% (in 2024) over the last 5 years.
  • Acadia Pharmaceuticals' Free Cash Flow (Yearly) stood at -$143.8 million in 2020, then increased by 11.81% to -$126.8 million in 2021, then increased by 10.05% to -$114.0 million in 2022, then soared by 114.60% to $16.7 million in 2023, then surged by 844.01% to $157.2 million in 2024.